Celgene, MorphoSys sign antibody drug deal worth up to $818M

Celgene and MorphoSys will collaborate in the development of the latter's fully human monoclonal antibody MOR202 for treatment of multiple myeloma and other indications in a deal worth as much as $818 million. The drug, which targets the CD38 protein, is in a Phase I/IIa study against relapsed/refractory melanoma. MorphoSys will get $92 million upfront and a $60 million investment from Celgene, in addition to possible milestone fees and sales royalties.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC